Joseph S. Zakrzewski - 23 Dec 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Purchase	$1,974	+200	+0.25%	$9.87	81,367	23 Dec 2021	Direct	F1
transaction	CYT	Common Stock	Purchase	$1,994	+200	+0.25%	$9.97	81,567	27 Dec 2021	Direct	F1
transaction	CYT	Common Stock	Purchase	$1,008	+99	+0.12%	$10.18	81,666	27 Dec 2021	Direct	F1
transaction	CYT	Common Stock	Purchase	$5,920	+601	+0.74%	$9.85	82,267	28 Dec 2021	Direct	F1, F2
holding	CYT	Common Stock						58,671	23 Dec 2021	See Footnote	F3
holding	CYT	Common Stock						149,051	23 Dec 2021	See Footnote	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	79,932 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $9.81 to $9.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F3	Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F4	Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.